Efficacy of Suppression of Serum Transthyretin With Patisiran and Vutrisiran in Variant ATTR Amyloidosis: An Observational Crossover Study
Authors:
- Yousuf RazviYRYousuf Razvi
- Muhammad Umaid RaufMRMuhammad Umaid Rauf
- Aldostefano PorcariAPAldostefano Porcari
- Josephine MansellJMJosephine Mansell
- Awais SheikhASAwais Sheikh
- Adam IoannouAIAdam Ioannou
- Carol J. WhelanCWCarol J. Whelan
- Lucia VenneriLVLucia Venneri
- Ana Martinez-NaharroAMAna Martinez-Naharro
- David F. HuttDHDavid F. Hutt
- Dorota RowczenioDRDorota Rowczenio
- Janet A. GilbertsonJGJanet A. Gilbertson
Open Access
- 3 February 2026
- journal article
- Published by Wolters Kluwer Health in Circulation
- Vol. 153 (5) , 364-366
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Vutrisiran in Patients with Transthyretin Amyloidosis with CardiomyopathyNew England Journal of Medicine, 2025
- Determinants of transthyretin levels and their association with adverse clinical outcomes among UK Biobank participantsNature Communications, 2024
- Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trialAmyloid, 2022
- Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapyBritish Journal of Haematology, 2003
- Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A proteinThe Lancet, 2001